More about Granules India Limited
Fundamentals for Granules India Limited
Regulatory Filings for Granules India Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Granules India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Revenue projections:
Revenues for GRANULES are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 19.964533 |
| debtToEquity | 45.369000 |
| earningsGrowth | 0.276000 |
| revenueGrowth | 0.220000 |
| grossMargins | 0.618960 |
| operatingMargins | 0.169010 |
| trailingEps | 22.460000 |
| forwardEps | 30.005710 |
Granules India Limited's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
Granules India Limited's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as Granules India Limited's increasing profits and sales signal further growth in the near future.
GRANULES's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that GRANULES's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.
Price projections:
Price projections for Granules India Limited have consistently been revised upward, suggesting that analysts are increasingly optimistic about the company's performance. This trend reflects a positive outlook for Granules India Limited's future.
Recommendation changes over time:
A recent buy bias from analysts toward GRANULES may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that GRANULES might be an appealing option for those looking to grow their wealth through stock market investments.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction